RDY Filings — Dr Reddy'S Laboratories Ltd

FilingSpy

RDY Filings — Dr Reddy'S Laboratories Ltd - FilingSpy

Last event

Aug 26

6-K

Events · 12 mo

122

8-K + 6-K

Earnings releases

Item 2.02 · 12 mo

Leadership changes

Item 5.02 · 12 mo

Aug 26, 20266-K

Dr. Reddy's Laboratories allots 4,110 equity shares under ESOP 2002 on August 26, 2026.

Exercise price per share was Re. 1, with no premium; shares rank pari passu with existing shares.

Show details

Allotted 4,110 fully paid-up equity shares of Re. 1 each to eligible employees under Dr. Reddy's Employees Stock Option Scheme, 2002.
Total issued share capital after allotment is Rs. 83,46,80,910, comprising 83,46,79,910 equity shares (excluding 1,000 forfeited shares).
Shares were allotted on August 26, 2026, with distinctive numbers 834675801 to 834679910 and ISIN INE089A01031.
The company listed on BSE, NSE, NYSE (ADRs), and NSE IFSC (ADRs) was informed under Regulation 30 of SEBI LODR.

Primary filing Press release

Aug 17, 20266-K

Dr. Reddy's receives USFDA Form 483 with four observations after GMP inspection

USFDA completed a GMP inspection at Dr. Reddy's formulations manufacturing facility FTO-3 in Bachupally, Hyderabad from August 6 to August 14, 2026.

Show details

The company was issued a Form 483 with four observations.
Dr. Reddy's stated it will address the observations within the stipulated timeline.
The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Primary filing Press release

Aug 17, 20266-K

USFDA closes Dr. Reddy's Mirfield API facility inspection as Voluntary Action Indicated

The inspection is officially closed under 21 CFR 20.64(d)(3).

Show details

The USFDA classified the GMP inspection at Dr. Reddy's API manufacturing facility in Mirfield, West Yorkshire, UK as 'Voluntary Action Indicated (VAI)'.
This update follows the company's prior intimation dated September 8, 2025, regarding the USFDA inspection.
The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Primary filing Press release

Aug 13, 2026Leadership6-K

Dr. Reddy's CEO of API and Services Deepak Sapra resigns effective November 12, 2026

He is leaving to pursue opportunities outside the company after over 23 years with Dr. Reddy's since 2003.

Show details

Deepak Sapra resigned as CEO, API and Services and Senior Management Personnel, effective from close of business on November 12, 2026.
He will support a smooth transition and handover of responsibilities until his departure.
The resignation was disclosed under Regulation 30 of the SEBI Listing Regulations to stock exchanges including NSE, BSE, NYSE, and NSE IFSC.

Primary filing Press release

Aug 10, 20266-K

Dr. Reddy's terminates Novartis India distribution agreement effective after Sept 30, 2026

The termination follows a change in controlling shareholding of NIL.

Show details

Dr. Reddy's Laboratories terminated its February 11, 2022 agreement with Novartis India Limited (NIL) for distribution and promotion of select brands in India.
Dr. Reddy's will continue to commercialize the covered brands until September 30, 2026.
The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Primary filing Press release

Aug 3, 20266-K

Dr. Reddy's receives U.S. FDA approval for rituximab biosimilar

Fresenius Kabi holds exclusive rights to commercialize the product in the United States.

Show details

The U.S. FDA approved Dr. Reddy's rituximab biosimilar, a biosimilar to Rituxan, for the U.S. market.
The product was developed, manufactured, and submitted by Dr. Reddy's, following a successful Pre-License Inspection at its Bachupally facility.
The biosimilar is already commercialized in India, the EU, the UK, and over 25 emerging markets, with approvals in Switzerland and Canada.
Approval was supported by evidence showing high similarity to the reference product with no clinically meaningful differences in safety, purity, or potency.

Primary filing Press release

Jul 29, 2026Earnings6-K

Dr. Reddy's Q1 FY27 revenue down 5.6% YoY, EBITDA margin 12.5% due to semaglutide provision

A ₹240 crore provision for inventory and other costs related to semaglutide API challenges impacted results.

Show details

Consolidated revenues were ₹8,071 crores (US$853 million), down 5.6% YoY, with EBITDA margin at 12.5%.
Excluding the semaglutide provision, EBITDA margin was 15.4%; management estimates high-teens excluding all semaglutide and Middle East impacts.
Semaglutide commercial supplies are planned to resume by November 2026.
North America Generics revenue declined 41% YoY to US$236 million due to lower lenalidomide sales, but base business grew double-digits.

Primary filing Press release

Jul 29, 20266-K

USFDA completes PAI/GMP inspection at Dr. Reddy's Srikakulam unit, issues Form 483 with 3 observations

Dr. Reddy's stated it will address the observations within the stipulated timeline.

Show details

USFDA conducted a Pre-Approval Inspection (PAI) and GMP inspection at Dr. Reddy's FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh from July 20 to July 29, 2026.
The company received a Form 483 with three observations following the inspection.
The disclosure was made under Regulation 30 of SEBI Listing Regulations to stock exchanges including NSE, BSE, NYSE, and NSE IFSC.

Primary filing Press release